KLOW Peptide Blend: What’s in It and What the Evidence Shows

KLOW is a marketing name for an injectable blend of four research peptides: GHK-Cu, BPC-157, TB-500 and KPV. GLOW is the same mix without KPV. No human trial has tested either blend, none of the four ingredients is FDA-approved, and most of the evidence for each one comes from cell and animal studies.¹

The name has spread fast through peptide forums and social media. The marketing usually promises skin, healing and gut benefits in one vial. The research behind those claims is thinner than the product pages suggest, and in one controlled animal study, combining two of the ingredients added nothing over either one alone.²

This guide explains what KLOW contains, what the evidence for each component actually shows, where the blend stands with the FDA and anti-doping bodies as of October 2026, and the practical risks of injecting unregulated multi-peptide products. It does not cover dosing or sourcing. For background on the wider category, see our research peptides hub.

At a glance: the KLOW peptide blend

Question	Short answer
What is in KLOW?	GHK-Cu, BPC-157, TB-500 and KPV, in ratios that vary by seller1
KLOW vs GLOW	GLOW drops KPV; the other three are the same1
Human trials of the blend	None found1
Best human evidence for any part	Topical GHK-Cu skin creams, not injections3
FDA status	Not approved; three components backed 8-6 by an advisory panel for compounding, with no rule issued4,5
Anti-doping status	BPC-157 and TB-500 prohibited at all times by WADA6
Main practical risks	Wrong or missing ingredients, contamination, endotoxin, injection-site infection7,8

What is KLOW peptide, and how does it differ from GLOW?

KLOW is not a single molecule. It is a pre-mixed vial of freeze-dried powder containing four separate peptides, sold mainly by “research use only” vendors. GLOW contains GHK-Cu, BPC-157 and TB-500. KLOW adds KPV, a short anti-inflammatory peptide, which is where the extra letter is usually said to come from.¹

No regulator, pharmacopoeia or clinical trial defines a standard KLOW formula. One consumer-health guide that reviewed the market notes that doses, ratios and purity vary from seller to seller.¹ That matters, because a “KLOW” vial from one seller is not necessarily the same product as a “KLOW” vial from another.

The four ingredients come from very different research traditions:

• GHK-Cu is a copper-binding tripeptide studied mostly in skin and wound biology. We compare it with BPC-157 in detail in GHK-Cu vs BPC-157.
• BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in gastric juice, studied mainly in rat injury models.⁹
• TB-500 is usually a short synthetic fragment linked to thymosin beta-4, a naturally occurring protein.¹⁰
• KPV is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone, studied for anti-inflammatory effects without the pigmenting action of the parent hormone.¹¹

KLOW peptide benefits: what the evidence for each component shows

Sellers and influencers typically frame KLOW as covering skin quality, tissue repair and inflammation at once. The honest way to assess that claim is component by component, because there is no blend-level data to look at. A 2026 review in Sports Medicine covering GHK-Cu, BPC-157, TB-500 and several other unapproved peptides concluded that many look favourable in animal models but that rigorous human safety data are scarce.¹²

GHK-Cu: real human data, but for skin creams

GHK-Cu has the most human research of the four, though almost all of it is cosmetic and topical. Reviews by the peptide’s original researcher, Loren Pickart, describe gene-expression effects and lab findings on collagen and tissue repair; both reviews are authored by people affiliated with a skin-care company, which readers should weigh.^13,3 The 2015 review summarises 12-week facial cream studies, including one in 71 women with photoaged skin and another in 67 women aged 50 to 59, reporting improvements in fine lines, firmness and skin density.³

Independent controlled data are more mixed. In a small randomised study of 13 patients using GHK-Cu skin-care products after CO2 laser resurfacing, blinded evaluators found no significant difference in redness, wrinkles or overall skin quality compared with products without it, although patients using GHK-Cu reported higher satisfaction.¹⁴

None of this tells us what injected GHK-Cu does. Applying a copper peptide to the skin and injecting it under the skin are different exposures, and we found no controlled human trials of injected GHK-Cu.

BPC-157: strong animal interest, almost no human data

A 2025 systematic review in HSS Journal identified 36 eligible studies on BPC-157 in orthopaedic sports medicine: 35 preclinical and one clinical.¹⁵ The single clinical study was a retrospective chart review in which 7 of 12 patients reported knee pain relief lasting more than six months. The review found no clinical safety data.¹⁵ A separate 2025 narrative review counted only three small human pilot studies in total and called BPC-157 investigational.⁹

The knee study itself, published in 2021, was a phone survey of 16 patients at a hormone clinic, with no control group and no validated outcome measures.¹⁶ Our guides to BPC-157 side effects and safety and BPC-157 vs TB-500 go further into those studies.

TB-500: a fragment, not the protein that was tested

Much of the healing research cited for TB-500 was done on thymosin beta-4, the full 43-amino-acid protein. Products sold as TB-500 often contain something else. When Belgian anti-doping scientists analysed a TB-500 product, they identified a seven-amino-acid acetylated fragment of thymosin beta-4 rather than the whole protein.¹⁰

The full protein has reached small human trials in other forms. A phase 2 trial of thymosin beta-4 eye drops in nine patients with severe dry eye reported improvements in symptoms and corneal staining versus a vehicle.¹⁷ That is an eye drop of a different molecule, so it does not support injected TB-500 for muscles, tendons or skin.

KPV: laboratory and mouse studies only

KPV’s evidence base is the thinnest. A frequently cited 2008 study in Gastroenterology found that KPV entered intestinal and immune cells through the PepT1 transporter, reduced inflammatory signalling in human cell lines, and reduced chemically induced colitis in mice when given in drinking water.¹⁸ That study used oral delivery in animals. We found no published human trials of KPV, injected or otherwise, in a search of PubMed.

Is there any evidence for the blend itself?

No. We found no human trial of KLOW, GLOW or any four-way combination of these peptides, and the consumer-health review of the market reached the same conclusion.¹ The ingredients have never been tested together for safety, interactions or stability in solution.

The closest evidence comes from a two-way combination. In a 2026 randomised study, 32 rats had their Achilles tendons cut and repaired, then received BPC-157, TB-500, both, or nothing for four weeks. Both peptides alone were associated with better tissue scores than controls, but the authors reported that combined BPC-157 and TB-500 treatment did not confer additional benefits over either peptide alone.² It is one small animal study, but it is the only controlled test we found of whether stacking two KLOW ingredients beats using one, and the answer was no. Our article on the Wolverine peptide stack covers that two-peptide combination in more depth.

Adding more peptides to a vial also adds unknowns. Each extra ingredient brings its own impurity profile, and there is no published data on whether these four degrade, react or aggregate when stored together.

Why “stack” marketing outpaces the evidence

Blends sell partly because they compress several hopeful stories into one product. GHK-Cu borrows credibility from skin-cream studies, BPC-157 and TB-500 from rat injury models, and KPV from colitis research in mice. Put together, the label implies a broader, stronger effect than any single study supports.

Three features of the evidence are easy to miss in that framing:

• Different routes. The best GHK-Cu data are topical, the KPV data are oral in mice, and the BPC-157 rat data use a mix of routes. None of it establishes what a combined injection does.
• Different molecules. TB-500 is not the same as the thymosin beta-4 protein used in most trials.¹⁰
• No synergy data. The one controlled combination study found no added benefit from pairing BPC-157 with TB-500.²

Reviewers have also pointed to placebo effects and social media as amplifiers of perceived benefit with unapproved peptides.¹² A tendon that was healing anyway can make any vial seem to work.

Is KLOW legal? FDA and regulatory status in 2026

None of KLOW’s four components is an FDA-approved drug, and no blend of them has ever been submitted for approval. Selling them for human use is a different question from whether a pharmacy can compound them, and both have moved this year.

Compounding. At its 23 to 24 July 2026 meeting, the FDA’s Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding BPC-157, KPV and TB-500 to the 503A bulks list, despite FDA staff recommending against all seven peptides reviewed.⁴ The votes are not binding. As of mid-October 2026, no peptide had been added to the list and no proposed rule had been issued.⁵ GHK-Cu was not part of that vote; it is among five peptides expected at a further committee meeting before the end of February 2027, with no date set.⁵ Our explainers on the 503A bulks list vote and the BPC-157 advisory vote cover the process.

Separately, the FDA’s safety-risk list for compounding now shows BPC-157, KPV, the TB-500 fragment and injectable GHK-Cu as nominations withdrawn from Category 2, the “significant safety risks” group.¹⁹ Leaving that list does not make a substance eligible for compounding.⁵

Interim access policy. On 14 October 2026, HHS and the FDA sent an “Interim Access Policy for Compounding Using Certain Peptides” to the White House Office of Management and Budget for review. It has not been issued, and law firm Holland & Knight expects it, if finalised, to take the form of enforcement discretion for state-licensed 503A pharmacies, not approval, and not to cover research-use-only sellers.⁵ Which peptides it would name is not public.

Enforcement against sellers. On 24 August 2026 the FDA issued warning letters to five online peptide vendors, concluding that “research use only” labels did not override website evidence, such as dosing calculators and bacteriostatic water sold alongside vials, that products were intended for human use.²⁰ Those letters named GLP-1 drugs and other peptides rather than KLOW ingredients, but an earlier March 2026 FDA warning letter applied the same reasoning.²¹ Our guide to what research use only actually means explains why the label offers buyers no safety assurance.

Sport. The World Anti-Doping Agency lists BPC-157 under S0 (non-approved substances) and thymosin beta-4 and its derivatives, such as TB-500, under S2. Both categories are prohibited at all times, in and out of competition.⁶ A KLOW vial therefore contains two banned substances for tested athletes.

KLOW peptide risks: purity, contamination and infection

The biggest known risks of KLOW are not about the biology of the peptides, which is largely unknown in people, but about what is actually in the vial and how it is used.

Identity and purity. A 2026 preprint, not yet peer reviewed, analysed more than 6,000 third-party test reports on consumer peptides. About 3.5% of BPC-157 samples and 10.0% of TB-500 samples did not contain the stated compound, and TB-500 had the lowest median purity of the 14 peptides covered.⁸ Blends were not analysed separately, and a four-peptide vial is harder to verify than a single one, because each ingredient needs its own identity and content result.

Endotoxin and microbes. In the same preprint, 15% of the samples with endotoxin data had measurable endotoxin, and high purity did not predict low endotoxin.⁸ Health Canada named BPC-157, GHK-Cu, KPV and TB-500 in an April 2026 advisory warning that unauthorised injectable peptides may contain the wrong amount of ingredient, unlisted substances, particles, bacteria, fungi or endotoxins, and can cause infections and allergic reactions.⁷

Injection-site problems. A recurring complaint in peptide forums is stinging or burning at the injection site with copper-containing blends. Local reactions can be minor, but redness that spreads, heat, swelling, pus or fever can signal infection and need prompt medical care.

Theoretical long-term concerns. A 2026 review in Missouri Medicine listed contamination, inaccurate dosing, pathological blood-vessel growth and possible cancer promotion among the potential risks of unapproved injectable peptides, including BPC-157 and TB-500.²² These are biologically plausible concerns rather than documented outcomes, which is exactly the problem: nobody has followed KLOW users long enough to know.

If you are evaluating test reports for any peptide, our guide to reading a peptide COA explains what identity, purity, content and endotoxin results should look like, and why a single “99% pure” figure tells you little about a blend.

KLOW vs Wolverine and other peptide stacks

“Wolverine” is the name commonly used for BPC-157 plus TB-500, without GHK-Cu or KPV. GLOW adds GHK-Cu to that pair, and KLOW adds KPV on top. So in ingredient terms, KLOW is the Wolverine pair plus two more peptides, not a different product family.

That means the questions people ask about “KLOW vs Wolverine” mostly come down to whether GHK-Cu and KPV add anything when injected alongside the other two. There is no human evidence to answer that, and the only controlled test of the core pair found no additive effect.² Our overview of common research peptide types puts these compounds in context with other peptides sold online.

What to do if you are considering KLOW

If you are drawn to KLOW for a tendon injury, skin ageing or gut symptoms, a clinician can point you to treatments with human evidence for that problem. If you have already used a blend and develop signs of infection, an allergic reaction or unexplained symptoms, seek medical care and take the vial and any packaging with you. Athletes subject to testing should treat any KLOW, GLOW or Wolverine product as containing prohibited substances.

Frequently asked questions

What is KLOW peptide?

KLOW is a marketing name for an injectable blend of four research peptides: GHK-Cu, BPC-157, TB-500 and KPV. It is sold mainly by research-use-only vendors, with ratios that vary between sellers. None of the four is FDA-approved, and no human trial has tested the blend. Most evidence for each ingredient comes from cell and animal studies.¹

What is the difference between KLOW and GLOW peptide?

GLOW contains GHK-Cu, BPC-157 and TB-500. KLOW is the same three peptides plus KPV, a short fragment of alpha-melanocyte-stimulating hormone studied for anti-inflammatory effects in cells and mice. There is no human evidence that adding KPV changes what the blend does, and neither product has been tested in a clinical trial.^1,18

Is KLOW the same as the Wolverine stack?

No, but they overlap. The Wolverine stack is BPC-157 plus TB-500. KLOW contains both of those peptides and adds GHK-Cu and KPV. The only controlled study we found of the core pair, in 32 rats with repaired Achilles tendons, reported no additional benefit from combining BPC-157 and TB-500 over either alone.²

Is KLOW peptide FDA-approved or legal?

No component of KLOW is FDA-approved. An FDA advisory committee voted 8-6 in July 2026 to recommend adding BPC-157, KPV and TB-500 to the compounding bulks list, but the vote is non-binding and no rule has been issued. The FDA has said research-use-only labels do not protect sellers whose products are clearly intended for human use.^4,5,20

Is KLOW safe to inject?

Its safety in people is unknown because the blend has never been studied. Known practical risks include products that lack the stated peptide, contamination, endotoxin and injection-site infection. In one 2026 preprint, 10.0% of TB-500 samples did not contain the labelled compound. Health Canada has warned against injecting peptides bought online.^7,8

Sources

1. Superpower. GLOW Peptide Blend: GHK-Cu, BPC-157, and TB-500, and How KLOW Differs. Peptide science guide. Accessed 25 October 2026. superpower.com
2. Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. DOI: 10.52312/jdrs.2026.2951. PMID: 42542926. pubmed.ncbi.nlm.nih.gov
3. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. DOI: 10.1155/2015/648108. PMID: 26236730. pubmed.ncbi.nlm.nih.gov
4. Steinzor P. FDA panel backs 6 peptides for compounding. AJMC. 31 July 2026. ajmc.com
5. Crossan SS, Watkins S. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight Alert. 16 October 2026. hklaw.com
6. World Anti-Doping Agency. The 2026 Prohibited List (S0 Non-approved substances; S2 Peptide hormones, growth factors, related substances and mimetics). wada-ama.org
7. Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm you. Public advisory, 9 April 2026. recalls-rappels.canada.ca
8. Mendias CL, Awan TM. Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance. Preprint (not peer reviewed), Preprints.org. 24 April 2026. DOI: 10.20944/preprints202604.1748.v1. preprints.org
9. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. DOI: 10.1007/s12178-025-09990-7. PMID: 40789979. pubmed.ncbi.nlm.nih.gov
10. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. DOI: 10.1002/dta.1402. PMID: 22962027. pubmed.ncbi.nlm.nih.gov
11. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. DOI: 10.1210/er.2007-0027. PMID: 18612139. pubmed.ncbi.nlm.nih.gov
12. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. DOI: 10.1007/s40279-026-02437-0. PMID: 41966639. pubmed.ncbi.nlm.nih.gov
13. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. DOI: 10.3390/ijms19071987. PMID: 29986520. pubmed.ncbi.nlm.nih.gov
14. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259. DOI: 10.1001/archfaci.8.4.252. PMID: 16847171. pubmed.ncbi.nlm.nih.gov
15. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. DOI: 10.1177/15563316251355551. PMID: 40756949. pubmed.ncbi.nlm.nih.gov
16. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435. pubmed.ncbi.nlm.nih.gov
17. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496. DOI: 10.1097/ICO.0000000000000379. PMID: 25826322. pubmed.ncbi.nlm.nih.gov
18. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. DOI: 10.1053/j.gastro.2007.10.026. PMID: 18061177. pubmed.ncbi.nlm.nih.gov
19. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 22 April 2026. fda.gov
20. Kundi A, Cowley EM, Golden S, Billan N. RUO-ined: Five Peptide Vendors Learn That ‘Research Use Only’ Is Not a Legal Strategy. ArentFox Schiff. 18 September 2026. afslaw.com
21. US Food and Drug Administration, CDER. Warning Letter: Gram Peptides (MARCS-CMS 721806). 31 March 2026. fda.gov
22. Moiz A, O’Keefe EL, O’Keefe JH. Dangers of Injectable Peptides and Other Unregulated “Biohacking” Drugs. Mo Med. 2026;123(4):337-343. PMID: 42757290. pubmed.ncbi.nlm.nih.gov

Featured image: Vials In A Row – LTR by ZaldyImg, CC BY 2.0. Cropped.

This article is for educational purposes only and is not medical or legal advice. Products discussed here are not intended to diagnose, treat, cure or prevent any disease. Laws vary by location and change often, so verify the rules that apply where you are. Always talk to a licensed healthcare provider before use, especially if you are under 21, pregnant or nursing, taking medication, or managing a health condition.